MSN Laboratories Gets CDSCO Panel Nod To Manufacture, Market Ferumoxytol Injection

Medically Reviewed By :  Dr. Kamal Kant Kohli
Written By :  Dr. Divya Colin
Published On 2024-07-10 12:30 GMT   |   Update On 2024-07-10 18:44 GMT
Advertisement

New Delhi: Accepting the pharmacokinetics study data and the published literature on global clinical trial data involving 112 Indian patients, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major MSN Laboratories to manufacture and market Ferumoxytol Injection 510 mg of elemental iron/17 mL (30 mg/ml).

However, this approval is subject to the condition that the firm conduct post-marketing surveillance (PMS) of the proposed drug.

This came after MSN Laboratories presented the pharmacokinetic study report of Ferumoxytol injection 510 mg of elemental iron/17 mL (30 mg/ml) along with published literature on global clinical trial data involving Indian patients carried out by the innovator.

Ferumoxytol injection is an iron replacement product that is used to treat iron deficiency anemia (not enough iron in the blood) in patients with chronic kidney disease (CKD) and in patients unable to take oral iron or who had taken oral iron in the past but did not work well.

At the recent SEC meeting for Hematology held on June 18, 2024, the expert panel reviewed the pharmacokinetic study report of Ferumoxytol injection 510 mg of elemental iron/17 mL (30mg/ml) along with published literature on global clinical trial data involving Indian patients carried out by the innovator.

The committee has reviewed the pharmacokinetics study data and found it acceptable.

The firm has also presented the published literature on global clinical trial data involving 112 Indian patients, which the expert panel found acceptable.

After detailed deliberation, the committee recommended the grant of permission to manufacture and market Ferumoxytol injection 510 mg of elemental iron/17 mL (30 mg/mL) with a condition to conduct a PMS study.

Accordingly, the expert panel suggested that the firm submit the PMS study protocol within 3 months from the date of approval to CDSCO.

Also Read:Zydus Lifscience Gets CDSCO Panel Nod to Manufacture, Market Nivolumab for Metastatic Non-small Cell Lung Cancer

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News